Drug Candidates in Retinitis Pigmentosa Therapeutics
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Drug</strong> <strong>Candidates</strong> <strong>in</strong> Ret<strong>in</strong>itis <strong>Pigmentosa</strong><br />
<strong>Therapeutics</strong> Pipel<strong>in</strong>e to Develop More as<br />
Gene Therapy<br />
enquiry@psmarketresearch.com<br />
www.psmarketresearch.com
Ret<strong>in</strong>itis <strong>Pigmentosa</strong> <strong>Therapeutics</strong><br />
Ret<strong>in</strong>itis <strong>Pigmentosa</strong> therapeutics pipel<strong>in</strong>e <strong>in</strong> 2017<br />
Ret<strong>in</strong>itis pigmentosa, also known as ret<strong>in</strong>itis, is a degenerative eye disease<br />
that occurs due to the progressive degeneration of the rod photoreceptor<br />
cells <strong>in</strong> the ret<strong>in</strong>a of eye. The study analyzed that the ret<strong>in</strong>itis pigmentosa<br />
therapeutics pipel<strong>in</strong>e comprises approximately 38 drug candidates <strong>in</strong><br />
different stages of development.<br />
Access Report Summary with Detailed TOC on “Ret<strong>in</strong>itis <strong>Pigmentosa</strong><br />
<strong>Therapeutics</strong> Pipel<strong>in</strong>e Analysis, 2017 - Cl<strong>in</strong>ical Trials & Results, Patents,<br />
Designations, Collaborations, and Other Developments” at:<br />
https://www.psmarketresearch.com/market-analysis/ret<strong>in</strong>itis-pigmentosatherapeutics-pipel<strong>in</strong>e-analysis
Ret<strong>in</strong>itis <strong>Pigmentosa</strong> <strong>Therapeutics</strong><br />
Insights on market segments<br />
Orphan drug designations from the regulatory bodies such as Food and<br />
<strong>Drug</strong> Adm<strong>in</strong>istration (FDA), European Medic<strong>in</strong>es Agency (EMA) and M<strong>in</strong>istry<br />
of Health, Labour and Welfare (MHLW) is a key driver for the development<br />
of pipel<strong>in</strong>e drugs, for treat<strong>in</strong>g ret<strong>in</strong>itis pigmentosa. Majority of the pipel<strong>in</strong>e<br />
drug candidates are be<strong>in</strong>g developed us<strong>in</strong>g the <strong>in</strong>travitreal route of<br />
adm<strong>in</strong>istration. HORAMA S.A. is <strong>in</strong> the process of develop<strong>in</strong>g two phase I/II,<br />
and one Pre-Cl<strong>in</strong>ical therapeutics for the treatment of ret<strong>in</strong>itis pigmentosa.
Ret<strong>in</strong>itis <strong>Pigmentosa</strong> <strong>Therapeutics</strong><br />
Maximum drugs be<strong>in</strong>g developed as gene therapy<br />
Many companies are <strong>in</strong>creas<strong>in</strong>gly emphasiz<strong>in</strong>g on the development of gene<br />
therapy candidates, due to their positive cl<strong>in</strong>ical results <strong>in</strong> the treatment of<br />
ret<strong>in</strong>itis pigmentosa. Based on molecule type, around 50.0% of the drug<br />
candidates <strong>in</strong> the ret<strong>in</strong>itis pigmentosa pipel<strong>in</strong>e are expected to be<br />
developed based on gene therapy.
Ret<strong>in</strong>itis <strong>Pigmentosa</strong> <strong>Therapeutics</strong><br />
Technological advancements spurr<strong>in</strong>g the growth<br />
of the ret<strong>in</strong>itis pigmentosa therapeutics pipel<strong>in</strong>e<br />
Technological advancements are spurr<strong>in</strong>g the pipel<strong>in</strong>e growth, for <strong>in</strong>stance,<br />
AAV vector manufactur<strong>in</strong>g platform was used <strong>in</strong> the development of AGTC-<br />
501 by the Applied Genetic Technologies Corp for the treatment of ret<strong>in</strong>itis<br />
pigmentosa<br />
Some of the key players develop<strong>in</strong>g drugs for the treatment of ret<strong>in</strong>itis<br />
pigmentosa <strong>in</strong>clude jCyte, Inc., Dompe Farmaceutici SpA, ProRet<strong>in</strong>a<br />
<strong>Therapeutics</strong>, S.L., and Recursion Pharmaceuticals Inc.
Ret<strong>in</strong>itis <strong>Pigmentosa</strong> <strong>Therapeutics</strong><br />
Download report sample at:<br />
https://www.psmarketresearch.com/market-analysis/ret<strong>in</strong>itispigmentosa-therapeutics-pipel<strong>in</strong>e-analysis/report-sample
GET IN TOUCH<br />
THANK YOU!<br />
For <strong>in</strong>formation regard<strong>in</strong>g permissions and other queries<br />
K<strong>in</strong>dly write to:<br />
enquiry@psmarketresearch.com<br />
US/Canada Toll-Free: 1-888-778-7886<br />
www.psmarketresearch.com
Change language